Facebook
Twitter
LinkedIn
Forward
Embracing Targeted Medical Therapies in Neurofibromatosis Type 1: Practical Principles for the Pediatric Hematology/Oncology Nurse
Designed to provide a comprehensive and highly interactive overview of novel and emerging data, as well as establish a foundational knowledge base of NF1 as a tumor predisposition syndrome, this activity will begin by identifying hallmark aspects of NF1 natural history and clinical presentation, reviewing updated diagnostic criteria, and describing the genetic etiology and complex pathophysiology that has historically made NF1-associated plexiform neurofibromas (PNs) so difficult to treat. Catalyzed by a dynamic case-based approach, attendees will then be guided through an expert-led exploration of emerging clinical trial data for targeted medical therapies in the setting of NF1-associated tumors, with particular emphasis on toxicity profiles and responsive strategies for anticipating, mitigating, and managing adverse events. Finally, premier clinical experts will examine the pivotal patient-facing role of the pediatric hem/onc nurse in the shifting NF1 treatment paradigm, and real-world patient cases will offer an opportunity to design interprofessional approaches to practical nursing challenges in NF1, including patient assessment, patient/parent education and answering difficult questions, effective emotional support tactics, drug toxicity mitigation tools, and expectation management.
Target Audience
This educational initiative is targeted to pediatric hematology/oncology nurses and nurse practitioners attending the 2022 APHON Annual Conference.
Learning Objectives
- Summarize recently-updated NF1 diagnostic criteria and recognize hallmark features of NF1 clinical presentation and disease progression in pediatric patients.
- Review the genetic etiology and multisystem pathophysiology of NF1 as a tumor predisposition syndrome, and emphasize the patient morbidity and traditional intractability of NF1-related plexiform neurofibromas (PNs)
- Use an interactive, patient-case–driven approach to:
- Evaluate completed, ongoing, and planned clinical trial data for MEK inhibitors and multi-receptor TKIs, including recent FDA-approved indications, in the management of NF1-associated tumors.
- Examine the toxicity profiles of approved and investigational NF1-targeted therapeutics, with emphasis on MEK inhibitors,and develop evidence-supported strategies to adaptively anticipate, mitigate, and manage adverse events.
- Elucidate the patient-facing role of the pediatric hem/onc nurse on the interprofessional NF1 treatment team, and identify real-world approaches to patient assessment, toxicity management, patient/family education, and establishing an emotional support infrastructure.
Presented by Creative Educational Concepts, LLC
Supported through an independent educational grant from Alexion.
Additional Information
| Attachment | Size |
|---|---|
 Handout and References | 3.42 MB |
| Clinical Tool | 233.75 KB |
5 min Welcome and Introductions/Pre-test
15 min What We Know: NF1 Natural History, Diagnostic Criteria, and Clinical Hallmarks in Pediatric Patients
20 min What We’re Learning: Renewing Patient Horizons with Targeted Therapeutics in NF1-associated Tumors
25 min How We Change the Future: Patient-centric MEK Inhibitor Management Strategies for the Pediatric Hem/Onc Nurse
10 min Conversations with the Experts: Audience Q&A/Post-test
AeRang Kim, MD, PhD
Associate Professor of Pediatrics
Director of Clinical Research
Division of Oncology
Children’s National Hospital
Washington, DC
Shannon Langmead, RN, MSN, CRNP, CNRN
Clinic Coordinator
The Johns Hopkins Comprehensive Neurofibromatosis Center
Baltimore, MD
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Planners/Faculty:
AeRang Kim, MD, PhD–has no relevant financial relationships to disclose in relation to the content of this activity.
Shannon Langmead, RN, MSN, CRNP, CNRN–has disclosed that she is an advisor or consultant to AstraZeneca.
Peer Reviewer:
Christina Allen, CRNP, DNP–has no relevant financial relationships to disclose in relation to the content of this activity.
CEC Staff/Planners:
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Jessica Hall–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing (ANCC)
This activity is designated for 1.25 contact hours.
Upon completion of a CNE request form, statements of credit for nurses will be issued within 30 business days.
Available Credit
- 1.25 ANCC
- 1.25 Participation